BIB
ProShares Ultra Nasdaq Biotechnology
Price Chart
Latest Quote
$84.95
+1.81 (+2.18%)
Current Price
| Previous Close | $83.14 |
| Open | $85.41 |
| Day High | $87.18 |
| Day Low | $84.58 |
| Volume | 21,570 |
Fund Information
| Quarterly Dividend / Yield | N/A / 0.58% |
| Net Assets | $73.66M |
| Expense Ratio | 0.95% |
| Category | Trading--Leveraged Equity |
| Fund Family | ProShares |
| Net Asset Value | $85.00 |
| Premium/Discount | -0.06% |
| Quarterly Dividend Yield | 0.58% |
| P/E Ratio | 24.06 |
| Exchange | NGM |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $81.79 |
| SMA50 | $82.90 |
| SMA200 | $77.30 |
| RSI | 50.17 |
| ATR | 3.1157 |
| Rel Volume | 3.49 |
Performance History
| Week | +8.81% |
| Month | +9.95% |
| Quarter | +10.29% |
| 6 Months | +6.11% |
| YTD | +6.68% |
| Year | +81.98% |
| 3 Years | +58.89% |
| 5 Years | -10.55% |
| 10 Years | +120.99% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $84.95 | 21,900 |
| 2026-06-16 | $83.11 | 4,500 |
| 2026-06-15 | $83.72 | 5,100 |
| 2026-06-12 | $82.65 | 5,500 |
| 2026-06-11 | $82.27 | 9,400 |
| 2026-06-10 | $78.07 | 5,900 |
| 2026-06-09 | $81.08 | 8,300 |
| 2026-06-08 | $78.67 | 5,100 |
| 2026-06-05 | $80.27 | 3,100 |
| 2026-06-04 | $83.08 | 6,000 |
| 2026-06-03 | $79.36 | 5,200 |
| 2026-06-02 | $76.69 | 6,900 |
| 2026-06-01 | $81.46 | 5,100 |
| 2026-05-29 | $84.59 | 2,700 |
| 2026-05-28 | $84.84 | 5,900 |
| 2026-05-27 | $83.06 | 2,600 |
| 2026-05-26 | $82.52 | 1,000 |
| 2026-05-22 | $81.97 | 6,000 |
| 2026-05-21 | $82.29 | 4,600 |
| 2026-05-20 | $81.15 | 10,700 |
| 2026-05-19 | $77.30 | 4,300 |
| 2026-05-18 | $77.26 | 12,200 |
About ProShares Ultra Nasdaq Biotechnology
The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.
đ° Latest News
Biopharma Stocks Rally After Trump Threatens 100% Pharmaceuticals Tariff
Investor's Business Daily âĸ 2025-09-26T20:22:07Z
Will Trump's Looming Tariffs Affect Pharma Profits In The Second Half Of 2025?
Investor's Business Daily âĸ 2025-07-16T20:05:59Z
Trump Threatens Up To 200% Tariffs On Drug Imports. The Market Doesn't Believe Him.
Investor's Business Daily âĸ 2025-07-08T20:27:27Z
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.